<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03575078</url>
  </required_header>
  <id_info>
    <org_study_id>STU 052018-073</org_study_id>
    <nct_id>NCT03575078</nct_id>
  </id_info>
  <brief_title>ARQ761 + PARP Inhibitor in Refractory Solid Tumors</brief_title>
  <official_title>PHASE 1 DOSE ESCALATION TRIAL OF β-LAPACHONE (ARQ761) IN COMBINATION WITH PARP INHIBITOR, OLAPARIB, FOR REFRACTORY, ADVANCED SOLID TUMORS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open Label, dose escalation in a 3+3 study design to establish the RP2D of the combination of&#xD;
      ARQ761 and a PARP inhibitor, Olaparib&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open Label, dose escalation in a 3+3 study design to establish the RP2D of the combination of&#xD;
      ARQ761 and a PARP inhibitor, Olaparib. This is an exploratory Phase 1 trial evaluating the&#xD;
      safety and tolerability of the combination of ARQ761 and Olaparib.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Project Never Initiated - no human subjects were enrolled and no data regarding humans was&#xD;
    collected or studied&#xD;
  </why_stopped>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Actual">May 15, 2019</completion_date>
  <primary_completion_date type="Actual">May 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase 1 Dose Escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose of ARQ761 in combination with Olaparib.</measure>
    <time_frame>Day 1-28</time_frame>
    <description>If a dose limiting toxicity (DLT) is observed in 1 out of 3 patients at a given dose level, up to 3 additional patients will be enrolled and treated at that dose level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose limiting toxicities</measure>
    <time_frame>4 weeks</time_frame>
    <description>DLT will be defined by the occurrence of any of the following toxicities possibly or probably related to treatment, during cycle 1 only:&#xD;
Grade 3 or 4 hemolysis or hemolytic anemia, except: Transfusion for hemolysis or hemolytic anemia will be considered a DLT only if Hgb &lt; 8.0 g/dL (Grade 3 anemia) (b) Any drug related grade 3 or grade 4 non-hematological toxicity, except alopecia, nausea, diarrhea and vomiting in the absence of optimal anti-diarrheal and/or anti-nausea medications (c)Grade 4 neutropenia lasting more than 7 days. (d) Platelets &lt;50,000/µl for longer than 7 days or any platelet count &lt;25,000/µl. (e) Grade 3 or 4 hyperbilirubinemia that does not recover to Grade 1 within 7 days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Maximum tolerated dose of ARQ761 in combination with Olaparib.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ761, Olaparib</intervention_name>
    <description>ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily</description>
    <arm_group_label>Maximum tolerated dose of ARQ761 in combination with Olaparib.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Patients with histologically or cytologically confirmed locally advanced or metastatic&#xD;
             solid tumors that have received standard of care for their disease and for which no&#xD;
             other approved therapy is available or if patient has declined other approved&#xD;
             therapies.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Performance status ECOG 0-1.&#xD;
&#xD;
          -  Measurable disease as per RECIST criteria 1.1.&#xD;
&#xD;
          -  Access to archival tissue (available unstained slides of tumor tissue).&#xD;
&#xD;
          -  Central venous access, such as a Portacath or Hickman Line.&#xD;
&#xD;
          -  Adequate organ and marrow function measured within 14 days prior to administration.&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry, for&#xD;
             the duration of study participation, and for 90 days following completion of therapy.&#xD;
             Should a woman become pregnant or suspect she is pregnant while participating in this&#xD;
             study, she should inform her treating physician immediately.&#xD;
&#xD;
          -  A female of child-bearing potential is any woman (regardless of sexual orientation,&#xD;
             having undergone a tubal ligation, or remaining celibate by choice) who meets the&#xD;
             following criteria:&#xD;
&#xD;
          -  Has not undergone a hysterectomy or bilateral oophorectomy; or Has not been naturally&#xD;
             postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in&#xD;
             the preceding 12 consecutive months).&#xD;
&#xD;
          -  Ability to understand and willing to sign a written informed consent. Patient is&#xD;
             willing and able to comply with the protocol for the duration of the study including&#xD;
             undergoing treatment and scheduled visits and examinations.&#xD;
&#xD;
          -  Patients must have a life expectancy ≥ 16 weeks.&#xD;
&#xD;
          -  At least one lesion, not previously irradiated, that can be accurately measured at&#xD;
             baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short&#xD;
             axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and&#xD;
             which is suitable for accurate repeated measurements.&#xD;
&#xD;
          -  Postmenopausal or evidence of non-childbearing status for women of childbearing&#xD;
             potential: negative urine or serum pregnancy test within 28 days of study treatment&#xD;
             and confirmed prior to treatment on day 1.&#xD;
&#xD;
          -  Postmenopausal is defined as:&#xD;
&#xD;
               1. Amenorrheic for 1 year or more following cessation of exogenous hormonal&#xD;
                  treatments&#xD;
&#xD;
               2. Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) levels in the&#xD;
                  post-menopausal range for women under 50&#xD;
&#xD;
               3. Radiation-induced oophorectomy with last menses &gt;1 year ago&#xD;
&#xD;
               4. Chemotherapy-induced menopause with &gt;1 year interval since last menses&#xD;
&#xD;
               5. Surgical sterilization (bilateral oophorectomy or hysterectomy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those whose adverse events from prior therapies have not recovered to ≤ grade 1 except&#xD;
             alopecia.&#xD;
&#xD;
          -  Patients receiving any systemic chemotherapy or radiotherapy (except for palliative&#xD;
             reasons) within 3 weeks prior to study treatment.&#xD;
&#xD;
          -  Concurrent therapy: No other concurrent anticancer or investigational therapy&#xD;
             permitted except as noted above.&#xD;
&#xD;
          -  Subjects with known, untreated and/or symptomatic brain metastases: Subjects with&#xD;
             known, treated brain metastases must be stable with no symptoms for four weeks after&#xD;
             completion of treatment, with image documentation required, and must either be off&#xD;
             steroids or on a stable dose of steroids for at least two weeks prior to protocol&#xD;
             enrollment.&#xD;
&#xD;
          -  Subjects with known leptomeningeal metastases are excluded, even if adequately&#xD;
             treated.&#xD;
&#xD;
          -  Patients with spinal cord compression are excluded unless considered to have received&#xD;
             definitive treatment for this and evidence of clinically stable disease for 28 days.&#xD;
&#xD;
          -  Subjects without known brain metastases do not require radiologic imaging prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Uncontrolled, intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, significant pulmonary disease (shortness of breath at rest or mild&#xD;
             exertion), uncontrolled infection or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to agent(s) or other agents used in study.&#xD;
&#xD;
          -  Pregnant or nursing subjects due to the potential for either congenital abnormalities&#xD;
             or harming infants who are being nursed, respectively.&#xD;
&#xD;
          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca,&#xD;
             ArQule staff and/or staff at the study site).&#xD;
&#xD;
          -  Previous enrollment in the present study.&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product during the&#xD;
             last 4 weeks.&#xD;
&#xD;
          -  Any previous treatment with PARP inhibitor, including olaparib.&#xD;
&#xD;
          -  Resting ECG with QTc &gt; 470 msec on 2 or more time points within a 24 hour period or&#xD;
             family history of long QT syndrome.&#xD;
&#xD;
          -  Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin,&#xD;
             clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir,&#xD;
             saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg.&#xD;
             ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout&#xD;
             period prior to starting olaparib is 2 weeks.&#xD;
&#xD;
          -  Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin,&#xD;
             rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or&#xD;
             moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout&#xD;
             period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3&#xD;
             weeks for other agents.&#xD;
&#xD;
          -  Patients with myelodysplastic syndrome/acute myeloid leukemia or with features&#xD;
             suggestive of MDS/AML.&#xD;
&#xD;
          -  Major surgery within 2 weeks of starting study treatment and patients must have&#xD;
             recovered from any effects of any major surgery.&#xD;
&#xD;
          -  Patients considered a poor medical risk due to a serious, uncontrolled medical&#xD;
             disorder, non-malignant systemic disease or active, uncontrolled infection. Examples&#xD;
             include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3&#xD;
             months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal&#xD;
             cord compression, superior vena cava syndrome, extensive interstitial bilateral lung&#xD;
             disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder&#xD;
             that prohibits obtaining informed consent.&#xD;
&#xD;
          -  Patients unable to swallow orally administered medication and patients with&#xD;
             gastrointestinal disorders likely to interfere with absorption of the study&#xD;
             medication.&#xD;
&#xD;
          -  Breast feeding women.&#xD;
&#xD;
          -  Immunocompromised patients, e.g., patients who are known to be serologically positive&#xD;
             for human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Patients with a known hypersensitivity to olaparib or any of the excipients of the&#xD;
             product.&#xD;
&#xD;
          -  Patients with a known hypersensitivity to ARQ761.&#xD;
&#xD;
          -  Patients with known active hepatitis (i.e. Hepatitis B or C) due to risk of&#xD;
             transmitting the infection through blood or other body fluids.&#xD;
&#xD;
          -  Previous allogenic bone marrow transplant or double umbilical cord blood&#xD;
             transplantation (dUCBT).&#xD;
&#xD;
          -  Whole blood transfusions in the last 120 days prior to entry to the study (packed red&#xD;
             blood cells and platelet transfusions are acceptable per 3.1.8).&#xD;
&#xD;
          -  Other malignancy within the last 5 years except: adequately treated non-melanoma skin&#xD;
             cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ&#xD;
             (DCIS), Stage 1, grade 1 endometrial carcinoma, or other solid tumors including&#xD;
             lymphomas (without bone marrow involvement) curatively treated with no evidence of&#xD;
             disease for ≥5 years.&#xD;
&#xD;
          -  Patients with a history of localized triple negative breast cancer may be eligible,&#xD;
             provided they completed their adjuvant chemotherapy more than three years prior to&#xD;
             registration, and that the patient remains free of recurrent or metastatic disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad Beg</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTexas Southwestern</affiliation>
  </overall_official>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 21, 2018</study_first_submitted>
  <study_first_submitted_qc>June 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

